Results 31 to 40 of about 929,355 (361)

Neutralizing hepatitis B [PDF]

Journal of Experimental Medicine, 2020
Despite an effective vaccine, hepatitis B virus (HBV) remains a major public health threat since chronic infection leads to liver disease and cancer. Hehle et al. (https://doi.org/10.1084/jem.20200840) discovered human-derived antibodies that potently neutralize the virus. Will this help a cure?
openaire   +2 more sources

Acute Hepatitis A and Hepatitis B Coinfection

ACG Case Reports Journal, 2021
ABSTRACT Hepatitis A (HAV) has emerged in outbreaks across the United States particularly in at-risk populations such as men who have sex with men, as well as patients with a history of drug use, homelessness, and incarceration. Immunization among these high-risk populations remains underused.
Lily Dara, Kali Zhou, Yao Liu, Brent Hiramoto   +3 more
openaire   +3 more sources

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: A population-based study [PDF]

, 2009
Background: Hepatitis B virus infection is a very common cause of chronic liver disease worldwide. It is estimated that 3 of Iranians are chronically infected with hepatitis B virus.
Abolghasemi, H., Amini-Kafiabad, S., Assari, S., Hosseini, M.R., Jamali, J., Maghsudlu, M., Malekzadeh, R., Merat, S., Nouraie, M., Pourshams, A., Radmard, A.R., Rezvan, H., Zaer-Rezaii, H., Zeid-Abadi-Nejhad, M.   +13 more
core  

Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-Naïve chronic HBV patients [PDF]

, 2013
Background: Immunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness.
Abedi, F., Alavian, S.M., Ataei, B., Azad, T.M., Daram, M., Fazeli, Z., Ghamari, S., Goodarzi, Z., Jazayeri, S.M., Judaki, M.A., Kalantari, E., Karimzadeh, H., Keyvani, H., Khedive, A., Mahabadi, M., Mahmoodi, M., Malekzadeh, R., Mansour-Ghanaei, F., Montazeri, G., Moradi, A., Nejatizadeh, A., Norouzi, M., Pourhosseingholi, M.A., Rafatpanah, H., Ramezani, F., Saberfar, E., Saberfiroozi, M., Samimirad, K., Sanei-Moghaddam, I., Sarizadeh, G., Sayad, B., Somi, M.H., Yaran, M., Ziee, M.   +33 more
core   +1 more source

Identifying barriers to hepatitis B and delta screening, prevention, and linkage to care among people who use drugs in Philadelphia, Pennsylvania, USA

Harm Reduction Journal
Background People who use drugs (PWUD) are at increased risk for blood-borne viruses, including hepatitis B (HBV) and delta (HDV). Despite the public health threats both viruses present, awareness remains low among at-risk communities and providers who ...
Beatrice Zovich, Catherine Freeland, Holly Moore, Kara Sapp, Anousha Qureshi, Amy Jessop, Rachel Holbert, Fiona Borondy-Jenkins, Quinn Plunkett, Chari Cohen   +9 more
doaj   +1 more source

Dismantling Barriers to Hepatitis B and Delta Screening, Prevention, and Linkage to Care among the PWUD Community in Philadelphia

Viruses
The prevalence of hepatitis B and delta viruses (HBV/HDV) among people who use drugs (PWUD) remains largely unknown. In the context of one Philadelphia-based harm reduction organization (HRO), this study aimed to assess HBV/HDV prevalence and facilitate ...
Beatrice Zovich, Catherine Freeland, Holly Moore, Kara Sapp, Anousha Qureshi, Rachel Holbert, Jason Zambrano, Daljinder Bhangoo, Chari Cohen, Richard W. Hass, Amy Jessop   +10 more
doaj   +1 more source

Hepatitis B in pregnancy

World Journal of Gastroenterology, 2012
Chronic hepatitis B virus (HBV) infection affects about 350 million individuals worldwide. Management of HBV infection in pregnancy is difficult because of several peculiar and somewhat controversial aspects. The aim of the present review is to provide a tool that may help physicians to correctly manage HBV infection in pregnancy.
Borgia G, Carleo MA, GAETA, Giovanni Battista, Gentile I.   +3 more
openaire   +5 more sources

Evolutionary interplay between viruses and R‐loops

FEBS Letters, EarlyView.
Viruses interact with specialized nucleic acid structures called R‐loops to influence host transcription, epigenetic states, latency, and immune evasion. This Perspective examines the roles of R‐loops in viral replication, integration, and silencing, and how viruses co‐opt or avoid these structures.
Zsolt Karányi, Zita Képes, Zoltán Szabó, Eszter Csoma, Lóránt Székvölgyi   +4 more
wiley   +1 more source

Single‐cell insights into the role of T cells in B‐cell malignancies

FEBS Letters, EarlyView.
Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley   +1 more source